Cronos Group Inc.

TSX:CRON.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.57 -0.27%

-$0.01 today

Market cap
$1.67B
Beta
1.25
P/E (TTM)
-488.1
EPS (TTM)
-$0.01
52W Low $2.54High $4.66

Volume 0.15M

Average 0.19M

CRON.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Cronos Group Inc.TSX: CRON.TO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $21.51M rose 112.2% year over year, behind the +356.7% change in trailing-twelve-month EBITDA.

Context

  • EBITDA amounted to 2.0% of revenue in FY2025, down 36.6 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $97.1M (+3403.1%) for the fiscal year ending Dec 2026, a step up from the +93.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.51M+342.7% QoQ
Last fiscal yearDec 2025
-$2.94M+93.5% YoY
LTMMar 2026
$47.83M+356.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+112.2%+60.2%-52.0 pp
1 year+93.5%+3403.1%+3309.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(2.94M) USD
Year-over-year change
+93.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CRON.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +356.7% is the highest of 6, against a peer median of +28.5%.
  • EBITDA amounts to 30.0% of revenue for CRON.TO, versus a peer median of 14.9%.
CRON.TO Competitors
EBITDA for CRON.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WELL.TOWELL Health Technologies Corp.LTM Mar 2026CA$219.35M CAD+256.2%+29.6%14.9%
EXE.TOExtendicare Inc.LTM Jun 2026CA$213.41M CAD+28.5%+52.7%10.8%
SIA.TOSienna Senior Living Inc.LTM Sep 2026CA$202.95M CAD+39.8%+16.4%18.3%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$65.18M CAD-6.0%+29.1%12.8%
CRON.TOCronos Group Inc.LTM Mar 2026$47.83M USD+356.7%—30.0%
TLRY.TOTilray Brands, Inc.LTM Feb 2026-$1.34B USD-106.7%—156.2%
Peer median (excluding CRON.TO) —+28.5%+29.3%14.9%

Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.02M87.54M87.03M117.5M149.15M
Cost of Revenue81.47M71.96M75.15M87.05M87.45M
Gross Profit(17.45M)15.58M11.88M30.45M61.7M
Gross Margin-27.3%17.8%13.7%25.9%41.4%
Research & Development21.66M13.25M5.83M4.22M4.53M
Selling, General & Admin120.67M101.64M80.74M76.74M75.01M
Operating Expenses272.09M128.01M96.48M106.91M79.54M
Depreciation & Amortization13.36M11.52M7.44M8.84M14.48M
EBITDA(150.79M)(93.81M)(72.28M)(45.37M)(2.94M)
EBITDA Margin-235.5%-107.2%-83.0%-38.6%-2.0%
Operating Income(289.54M)(112.44M)(84.6M)(76.46M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income8.92M21.84M52.07M49.52M40.66M
Interest Expense00000
Other Income / Expenses162.1M(9.66M)11.1M113.01M419.21K
Income Before Tax(127.44M)(122.1M)(73.49M)36.55M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(427.41K)34.48M(3.23M)(3.44M)(14.44M)
Net Income(392.81M)(170.26M)(73.79M)41.04M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(0.34)(0.42)(0.18)0.10(0.03)
EPS (Diluted)(0.34)(0.42)(0.18)0.10(0.03)
Weighted Avg Shares369.73M370.39M380.96M382.16M383.47M
Weighted Avg Shares (Diluted)370.39M370.39M380.96M382.16M383.47M

Cronos Group Inc.

TSX:CRON.TO

Intrinsic Alpha fair value

Locked

Current Price

$4.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.